Embed Code
GW Pharmaceuticals, a trailblazer in the realm of #0excludeGlossary medicine, has been instrumental in transforming the landscape of cannabis therapeutics. Established in 1998 by Dr. Geoffrey Guy and Dr. Brian Whittle, the company has dedicated itself to exploring the medicinal benefits of cannabis, particularly focusing on cannabinoids. The name “GW Pharmaceuticals” is derived from the initials of its founders, reflecting their commitment to advancing cannabis science. The company’s flagship product, Epidiolex, received FDA approval in 2018, marking a historic moment as the first cannabis-derived drug sanctioned for medical use in the United States. This milestone not only underscored the therapeutic potential of cannabis but also paved the way for further research and acceptance of cannabinoid-based treatments. As the cannabis industry continues to expand, GW Pharmaceuticals stands at the cutting edge, leading the charge in developing innovative solutions that harness the power of cannabis for health and wellness. For further reading, visit [GW Pharmaceuticals on Wikipedia](https://en.wikipedia.org/wiki/GW_Pharmaceuticals).
GW Pharmaceuticals Limited is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.
![]() | |
Formerly |
|
---|---|
Company type | Subsidiary |
Nasdaq: GWPH | |
Industry | Pharmaceutical industry |
Founded | 1998; 27 years ago (1998) |
Founder |
|
Headquarters | Cambridge, United Kingdom |
Key people | Justin Gover (CEO) |
Products |
|
Revenue | ![]() |
![]() | |
Total assets | ![]() |
Total equity | ![]() |
Number of employees | 1,161 (2020) |
Parent | Jazz Pharmaceuticals |
Website | gwpharm![]() |
Footnotes / references |